These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Mediastinal germ cell tumor presenting with bone marrow metastases: an unusual pattern of relapse demonstrated with (18)F-FDG PET-CT. Sharma P; Sudhir SK; Dhull VS; Jain TK; Bal C; Kumar R Rev Esp Med Nucl Imagen Mol; 2014; 33(3):187-8. PubMed ID: 24076038 [No Abstract] [Full Text] [Related]
5. [A Case of Metastatic Seminomatous Testicular Tumor with Complicated Diagnosis by FDG-PET]. Hashizume A; Mizuno N; Kawai M; Kishida T Hinyokika Kiyo; 2016 Jul; 62(7):383-7. PubMed ID: 27569358 [TBL] [Abstract][Full Text] [Related]
6. The role of Hung TJ; McLean L; Mitchell C; Pascoe C; Lawrentschuk N; Murphy DG; Iravani A; Singh D; Hofman MS; Zidan L; Akhurst T; Lewin J; Hicks RJ Cancer Imaging; 2019 May; 19(1):28. PubMed ID: 31142361 [TBL] [Abstract][Full Text] [Related]
7. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Lassen U; Daugaard G; Eigtved A; Højgaard L; Damgaard K; Rørth M Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):396-402. PubMed ID: 12634968 [TBL] [Abstract][Full Text] [Related]
8. [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors]. Müller-Mattheis V; Reinhardt M; Gerharz CD; Fürst G; Vosberg H; Müller-Gärtner HW; Ackermann R Urologe A; 1998 Nov; 37(6):609-20. PubMed ID: 9887489 [TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of patients with nonseminomatous germ cell tumours and negative postchemotherapy positron emission tomography. Buchler T; Simonova K; Fencl P; Jarkovsky J; Abrahamova J Cancer Invest; 2012 Jul; 30(6):487-92. PubMed ID: 22506657 [TBL] [Abstract][Full Text] [Related]
10. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients. Cremerius U; Wildberger JE; Borchers H; Zimny M; Jakse G; Günther RW; Buell U Urology; 1999 Nov; 54(5):900-4. PubMed ID: 10565755 [TBL] [Abstract][Full Text] [Related]
11. [Positron emission tomography in the diagnosis and monitoring of patients with nonseminomatous germ cell tumours]. Büchler T; Simonová K; Fencl P; Abrahámová J Klin Onkol; 2011; 24(6):413-7. PubMed ID: 22257229 [TBL] [Abstract][Full Text] [Related]
12. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. de Wit M; Brenner W; Hartmann M; Kotzerke J; Hellwig D; Lehmann J; Franzius C; Kliesch S; Schlemmer M; Tatsch K; Heicappell R; Geworski L; Amthauer H; Dohmen BM; Schirrmeister H; Cremerius U; Bokemeyer C; Bares R Ann Oncol; 2008 Sep; 19(9):1619-23. PubMed ID: 18453520 [TBL] [Abstract][Full Text] [Related]
13. The role of CT scanning in the surveillance of testicular tumours. Nathan PD; Rustin GR Clin Oncol (R Coll Radiol); 2003 May; 15(3):121-2. PubMed ID: 12801048 [No Abstract] [Full Text] [Related]
14. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. Spermon JR; De Geus-Oei LF; Kiemeney LA; Witjes JA; Oyen WJ BJU Int; 2002 Apr; 89(6):549-56. PubMed ID: 11942962 [TBL] [Abstract][Full Text] [Related]